Skip to content
The People's CodeSearch
Menu

Changes to the Code

S. 2770 · Share the Savings with Seniors Act ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

42 U.S.C. § 1395w–102 Prescription drug benefits

+35 −2Shown
More for 42 U.S.C. § 1395w–102
Read § 1395w–102Only this section
4 changes the bill asks for here, 4 carried out
  1. Carried out:

    in paragraph (1)(A), in the matter preceding clause (i), by striking and (9) and inserting , (9), and (10);

  2. Carried out:

    in paragraph (2)(A), in the matter preceding clause (i), by striking and (9) and inserting , (9), and (10); and

  3. Carried out:

    by adding at the end the following new paragraph:(10) Cost-sharing for chronic care drugs.— (A) In general.— For plan years beginning on or after January 1, 2027, in the case of a chronic care drug, the following shall apply: (i) For costs below the annual deductible specified in paragraph (1), cost-sharing for such drug shall …

  4. Carried out:

    in subsection (c), by adding at the end the following new paragraph:(7) Cost-sharing for covered chronic care drugs.— The coverage is provided in accordance with subsection (b)(10)..

§ 1395w–102(b)Standard prescription drug coverage(1)–(2)

Start of § 1395w–102 to (a)(5) unchanged ·

(b) Standard prescription drug coverage For purposes of this part and part C, the term “standard prescription drug coverage” means coverage of covered part D drugs that meets the following requirements:

(1) Deductible

(A) In general Subject to paragraphs (8) [struck: and][inserted: ,] (9), [inserted: and (10), ]the coverage has an annual deductible—

(i) for 2006, that is equal to $250; or

(ii) for a subsequent year, that is equal to the amount specified under this paragraph for the previous year increased by the percentage specified in paragraph (6) for the year involved.

(B) Rounding Any amount determined under subparagraph (A)(ii) that is not a multiple of $5 shall be rounded to the nearest multiple of $5.

(2) Benefit structure

(A) 25 percent coinsurance Subject to subparagraphs (C), (D), and (E) and paragraphs (8) [struck: and][inserted: ,] (9), [inserted: and (10), ]the coverage has coinsurance (for costs above the annual deductible specified in paragraph (1) and up to the initial coverage limit under paragraph (3) for a year preceding 2025 and for costs above the annual deductible specified in paragraph (1) and up to the annual out-of-pocket threshold specified in paragraph (4)(B) for 2025 and each subsequent year) that is—

(i) equal to 25 percent; or

(ii) actuarially equivalent (using processes and methods established under section 1395w–111(c) of this title) to an average expected payment of 25 percent of such costs.

§ 1395w–102(b)–(c)

(b)(2)(B)–(9)(D) unchanged ·

(III) an amount equal to 25 percent of the negotiated price of the covered insulin product under the prescription drug plan or MA–PD plan.

(E) Special rule for first 3 months of 2023 With respect to a month’s supply of a covered insulin product dispensed during the period beginning on January 1, 2023, and ending on March 31, 2023, a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan shall reimburse an enrollee within 30 days for any cost-sharing paid by such enrollee that exceeds the cost-sharing applied by the prescription drug plan or MA–PD plan under subparagraph (B)(i) at the point-of-sale for such month’s supply.

(10) [inserted: Cost-sharing for chronic care drugs.—]

(A) [inserted: In general.—] [inserted: For plan years beginning on or after January 1, 2027, in the case of a chronic care drug, the following shall apply:]

(i) [inserted: For costs below the annual deductible specified in paragraph (1), cost-sharing for such drug shall not exceed the net price of such drug.]

(ii) [inserted: Subject to subparagraph (B), for costs above the annual deductible specified in paragraph (1) and below the out-of-pocket threshold specified in paragraph (4), any coinsurance amount for such drug shall be based on a percentage of the net price of such drug.]

(B) [inserted: Exception.—] [inserted: The requirement under subparagraph (A)(ii) shall not apply to a chronic care drug under a prescription drug plan if the cost-sharing amount for such drug under such plan is based on a copayment that is not tied to a percentage of a drug price (such as the negotiated price, list price, or wholesale acquisition cost), a drug benchmark price (such as the average wholesale price), or a drug cost.]

(C) [inserted: Definitions.—] [inserted: In this paragraph:]

(i) [inserted: Chronic care drug.—] [inserted: The term “chronic care drug” means a covered part D drug that is included under any of the following United States Pharmacopeia Convention (USP) categories and classes of drugs, as included in the most recent version of the USP Medicare Model Guidelines:]

(I) [inserted: Blood glucose regulators, other than insulins.]

(II) [inserted: Anti-inflammatories, inhaled corticosteroids.]

(III) [inserted: Bronchodilators, anticholinergic.]

(IV) [inserted: Bronchodilators, sympathomimetic.]

(V) [inserted: Respiratory tract agents, other.]

(VI) [inserted: Anticoagulants.]

(VII) [inserted: Cardiovascular agents, other.]

(VIII) [inserted: Any category or class identified by the Secretary or USP as a successor to the categories and classes described in subclauses (I) through (VII) based on the most recent USP Medicare Model Guidelines at the time of such identification.]

(ii) [inserted: Net price.—] [inserted: The term “net price” means the negotiated price of the drug net of all price concessions originating from manufacturers that are received or expected to be received by the plan or pharmacy benefit manager on behalf of the plan for such product and that are not already reflected in the negotiated price.]

(c) Alternative prescription drug coverage requirements A prescription drug plan or an MA–PD plan may provide a different prescription drug benefit design from standard prescription drug coverage so long as the Secretary determines (consistent with section 1395w–111(c) of this title) that the following requirements are met and the plan applies for, and receives, the approval of the Secretary for such benefit design:

(1) Assuring at least actuarially equivalent coverage

§ 1395w–102(c)–(d)

(c)(1)(A)–(4) unchanged ·

(5) Treatment of cost-sharing for adult vaccines recommended by the Advisory Committee on Immunization Practices The coverage is in accordance with subsection (b)(8).

(6) Treatment of cost-sharing for covered insulin products The coverage is provided in accordance with subsection (b)(9).

(7) [inserted: Cost-sharing for covered chronic care drugs.—] [inserted: The coverage is provided in accordance with subsection (b)(10).]

(d) Access to negotiated prices

(1) Access

(A) In general Under qualified prescription drug coverage offered by a PDP sponsor offering a prescription drug plan or an MA organization offering an MA–PD plan, the sponsor or organization shall provide enrollees with access to negotiated prices used for payment for covered part D drugs, regardless of the fact that no benefits may be payable under the coverage with respect to such drugs because of the application of a deductible or other cost-sharing or, for a year preceding 2025, an initial coverage limit (described in subsection (b)(3)).

Rest of § 1395w–102 unchanged ·

42 U.S.C. § 1395w–114 Premium and cost-sharing subsidies for low-income individuals

+1 −1Shown
More for 42 U.S.C. § 1395w–114
Read § 1395w–114Only this section
1 change the bill asks for here, 1 carried out
  1. Carried out:

    Section 1860D–14(a)(1)(D)(iii) of the Social Security Act (42 U.S.C. 1395w–114(a)(1)(D)(iii)) is amended by adding at the end the following new sentence: For plan year 2027 and subsequent plan years, the copayment amount applicable under the first sentence of this subclause for a chronic drug (as defined in section 1860D–2(b)(10)(B)) furnished to the individual may not exceed the applicable cost-sharing for such drug under the prescription drug plan or MA–PD plan in which the individual is enrolled..

§ 1395w–114(a)Income-related subsidies for certain individuals(1)–(2)

Start of § 1395w–114 to (a)(1)(D)(ii)(II)(bb) unchanged ·

(cc) for a drug not described in either item (aa) or (bb), the dollar amount applied under this clause for such a drug for the preceding plan year, increased in the manner specified in item (bb), or, if less, the copayment amount applicable to an individual under clause (iii).

Any amount established under item (bb) or (cc) of subclause (II), that is based on an increase of $1 or $3, that is not a multiple of 5 cents or 10 cents, respectively, shall be rounded to the nearest multiple of 5 cents or 10 cents, respectively.

(iii) Other individuals Subject to paragraph (6), in the case of an individual not described in clause (i) or (ii), the substitution for the beneficiary coinsurance described in section 1395w–102(b)(2) of this title (for all amounts through the total amount of expenditures at which benefits are available under section 1395w–102(b)(4) of this title) of a copayment amount that does not exceed the copayment amount specified under section 1395w–102(b)(4)(A)(i)(I)(aa) of this title for the drug and year involved. For plan year 2023 and subsequent plan years, the copayment amount applicable under the preceding sentence to a month’s supply of a covered insulin product (as defined in section 1395w–102(b)(9)(C) of this title) dispensed to the individual may not exceed the applicable copayment amount for the product under the prescription drug plan or MA–PD plan in which the individual is enrolled.[inserted: For plan year 2027 and subsequent plan years, the copayment amount applicable under the first sentence of this subclause for a chronic drug (as defined in section 1860D–2(b)(10)(B)) furnished to the individual may not exceed the applicable cost-sharing for such drug under the prescription drug plan or MA–PD plan in which the individual is enrolled.]

(E) Elimination of cost-sharing above annual out-of-pocket threshold For a year preceding 2024, the elimination of any cost-sharing imposed under section 1395w–102(b)(4)(A) of this title or under section 1395w–102(b)(9) of this title in the case of a covered insulin product (as defined in subparagraph (C) of such section).

(2) Other low-income individuals With respect to a plan year beginning before January 1, 2024, in the case of a subsidy eligible individual who is not described in paragraph (1), the individual is entitled under this section to the following:

Rest of § 1395w–114 unchanged ·

Step through the changes